These compounds were able to kill the patients’ Tregs isolated from ovarian cancer ascites more potently than those from healthy donors, supposedly due to the high TNFR2 expression on TME-infiltrating Tregs. The gene discussed is TNFRSF1B; the disease is ovarian carcinoma.